BIOCYTOGEN PHARMA. H YC1 (I54) — Working Capital to Net Assets Ratio
BIOCYTOGEN PHARMA. H YC1 (I54) has a Working Capital to Net Assets ratio of 55.9% as of December 2025. Working capital of €1.22 Billion (current assets of €2.15 Billion minus current liabilities of €930.31 Million) is measured against net assets of €2.18 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See I54 equity financing ratio to measure how much of total assets are equity-financed.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
BIOCYTOGEN PHARMA. H YC1 Working Capital to Net Assets (2021–2025)
This chart shows how BIOCYTOGEN PHARMA. H YC1's Working Capital to Net Assets ratio has evolved across 5 annual periods from 2021 to 2025. As of December 2025, the ratio stands at 55.9%, reflecting working capital of €1.22 Billion against net assets of €2.18 Billion EUR. Check BIOCYTOGEN PHARMA. H YC1 (I54) tangible net worth to evaluate the tangible quality of the company's equity base.
Annual Working Capital to Net Assets for BIOCYTOGEN PHARMA. H YC1 (2021–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for BIOCYTOGEN PHARMA. H YC1 from 2021 to 2025, covering 5 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see market cap of BIOCYTOGEN PHARMA. H YC1.
| Year | WC/NA Ratio | Working Capital (EUR) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 55.9% | €1.22 Billion | €2.18 Billion | €2.15 Billion | €930.31 Million | ▲ +22.3 pp |
| 2024 | 33.6% | €281.62 Million | €838.60 Million | €816.53 Million | €534.91 Million | ▲ +15.2 pp |
| 2023 | 18.4% | €145.43 Million | €790.44 Million | €723.05 Million | €577.62 Million | ▼ -8.8 pp |
| 2022 | 27.2% | €313.25 Million | €1.15 Billion | €919.30 Million | €606.05 Million | ▼ -6.9 pp |
| 2021 | 34.2% | €427.68 Million | €1.25 Billion | €874.24 Million | €446.56 Million | — |